MAR 11, 2019 9:12 PM PDT

PARP Inhibitors Boost Immune Efficacy

WRITTEN BY: Nouran Amin

In a recent research study, precision cancer drugs called PARP inhibitors are previously known to boost the immune system were found to spark a powerful immune response when used against cancer cells with weaknesses in DNA repair.

Image: Purple lung cancer cells. Credit: Anne Weston, Francis Crick Institute. Licence: CC BY-NC 4.0

"The findings of this study substantially change our understanding of how PARP inhibitors work. We now know that they not only kill tumors by damaging their DNA, but also by attracting immune cells to attack them -- acting as a sort of double-pronged attack. Immunotherapy is a genuinely brilliant cancer treatment but generally only for the 10 to 20 percent of people who respond to it. Finding the tumour is half of the battle in immunotherapy so by attracting the immune cells to the tumour, PARP inhibitors could enable the immunotherapy drug to target their attack,” says Chris Lord, Professor of Cancer Genomics at The Institute of Cancer Research in London.

Learn more:

Findings of the study were published in the Journal of Clinical Investigation and changes the current understanding on PARP inhibitors and their potential role in cancer treatments alongside immunotherapies. Particularly, certain PARP inhibitors, like olaparib, block a mechanism that cells use to repair DNA.

"Our study found that PARP inhibitors enlist immune cells to aid in the killing of cancer cells. This provides a rationale for using PARP inhibitors alongside immunotherapies to further stimulate the immune response to cancer cells with DNA repair defects and enhance the therapeutic benefit of the treatment. This will be evaluated in a clinical trial of lung, prostate and bladder cancers, which is starting later this year,” says study co-leader Dr. Sophie Postel-Vinay, Clinician Scientist and Medical Oncologist at Gustave Roussy, France, and The Institute of Cancer Research.

Source: The Institute of Cancer Research

 

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 15, 2022
Drug Discovery & Development
First Drug for Sleep Apnea Shows Promise in Patients
APR 15, 2022
First Drug for Sleep Apnea Shows Promise in Patients
A new drug for sleep apnea could reduce breathing pauses during sleep by over 20 per hour. The corresponding study was p ...
APR 28, 2022
Immunology
Lipid Supplement May Reduce Inflammation in MS
APR 28, 2022
Lipid Supplement May Reduce Inflammation in MS
Administration of an inflammation-mediating lipid has shown promise in reducing multiple sclerosis-related inflammation ...
MAY 12, 2022
Drug Discovery & Development
Gut Bacteria Composition Predicts Resposnse to Statins
MAY 12, 2022
Gut Bacteria Composition Predicts Resposnse to Statins
The composition of the gut microbiome is predictive of patient responses to statins. The corresponding study was publish ...
MAY 26, 2022
Cannabis Sciences
Cannabis Crystal Polymorphism
MAY 26, 2022
Cannabis Crystal Polymorphism
A new published commentary in the Journal of Cannabis Research indicated that cannabis crystallinity may determine level ...
JUN 09, 2022
Cardiology
Supplements and Heart Health
JUN 09, 2022
Supplements and Heart Health
There is little evidence that supplements actually improve heart health.
JUN 10, 2022
Cannabis Sciences
Are Cannabis Users Nicer?
JUN 10, 2022
Are Cannabis Users Nicer?
A study published in Nature offers evidence that cannabis has a positive effect on the psychosocial health of young adul ...
Loading Comments...